Cortisol dysregulation has been proposed to be involved in depression. Hypothalamic-pituitary-adrenal (HPA) axis dysregulation associated with major depressive disorder (MDD) was previously reported to be higher in the elderly. Furthermore, insulin resistance and the prevalence of type 2 diabetes are known to increase with aging. The aim of the present study was to determine whether a relationship existed between plasma cortisol levels following the dexamethasone/corticotrophin-releasing hormone (DEX/ CRH) test and insulin resistance evaluated by the homeostasis model assessment of insulin resistance (HOMA-R) in elderly MDD subjects. Fifteen unmedicated MDD inpatients and 17 age-and sex-matched healthy controls participated in this study. After overnight fasting, blood samples were collected to measure plasma glucose and insulin concentrations, estimate HOMA-R, and perform the DEX/CRH test to evaluate HPA axis function. The value of the area under the time curve of plasma cortisol concentrations (Cort AUC ) and peak cortisol values (Cort peak ) following the administration of DEX/CRH both correlated with HOMA-R in MDD group. In contrast, neither Cort AUC nor Cort peak correlated with HOMA-R in controls. This is the first study to directly demonstrate the relationship between HPA axis dysregulation assessed with the DEX/CRH test and the index of insulin resistance estimated as HOMA-R in elderly MDD patients.
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Introduction
A relationship has been identified between MDD and type 2 diabetes, which have also been proposed to partially share a common etiology (Iwata et al., 2013) ; MDD was shown to increase the incidence of type 2 diabetes (relative hazard [RH] 1.63, 95% CI 1.31-2.02) (Golden et al., 2004) and the comorbidity rate of MDD in type 2 diabetic patients was estimated to be higher than that in the non-diabetic population (Gavard et al., 1993) . A meta-analysis performed by Gavard et al. (1993) revealed that the prevalence of depression in current diabetic patients ranged between 8.5% and 27.3% (mean¼ 14.0%), which was three-fold higher than the prevalence of MDD in the general adult population.
The risk factors for MDD in diabetic patients include the burden of diabetes management and arteriosclerosis (Schillerstrom et al., 2008) . On the other hand, the risk factors for diabetes in patients with depression involve reduced daily activities, overeating, and hypercortisolemia (Pariante and Lightman, 2008) . Hypercortisolemia has been attributed to hypothalamic-pituitary-adrenal (HPA) axis dysregulation, which is one of the most reliable biological findings of MDD (Pariante and Lightman, 2008) , has been implicated in the development of insulin resistance (Manoudi et al., 2012) , and is a risk factor for type 2 diabetes (Brown et al., 2004) . However, evidence for the relationship between hypercortisolemia and insulin resistance is limited to a cross-sectional study that only recruited normal volunteers (Rizza et al., 1982) . This study demonstrated that cortisol-induced insulin resistance was caused by a decrease in both hepatic and extrahepatic sensitivity to insulin.
HPA axis dysregulation associated with MDD was previously shown to be more prevalent in the elderly (Hatzinger et al., 2011) , and insulin resistance and the prevalence of type 2 diabetes have both been reported to increase with aging (Rowe et al., 1983) . Regarding depression, community-based studies identified a relationship between aging and prevalence of MDD (Beekman et al., 1999; Naismith et al., 2012) . Moreover, a meta-analysis revealed that aging itself may be an important risk factor for MDD (Snowdon, 2001) . A previous study also found that the prevalence of type 2 diabetes was the highest in the elderly (Danaei et al., 2011) . Taken together, these findings suggested that a positive relationship exists between hypercortisolemia arising from HPA axis dysregulation and insulin resistance in elderly MDD patients.
Elevated cortisol levels have been shown to worsen glucose tolerance (Di Dalmazi et al., 2012) . Insulin resistance may aggravate type 2 diabetes and cardiovascular disease, but not hypercortisolemia, which may develop due to the excess secretion of adrenocorticotrophic hormone (ACTH) or administration of a glucocorticoid treatment, but not directly from insulin resistance (Meigs, 2003; Prague et al., 2013) . Therefore, we hypothesized that depression or depressive episodes may have effects on cortisol dysregulation and also that the resultant hypercortisolemia may subsequently lead to the development of insulin resistance in patients with depression. In the present study, we investigated whether hypercortisolemia resulting from HPA axis dysregulation was directly associated with insulin resistance in elderly MDD patients. The primary aim of the present study was to determine whether plasma cortisol levels following the dexamethasone/corticotrophin-releasing hormone (DEX/CRH) test correlated with insulin resistance evaluated with HOMA-R in elderly MDD subjects.
Methods

Subjects
Fifteen unmedicated inpatients from the psychiatry ward, Tottori University Hospital, Yonago, Japan and 17 age-and sex-matched controls participated in this study with written informed consent between November 2008 and December 2012 following a full explanation of the study. All were older than 60 years. Fifteen inpatients met the criteria of MDD from the Diagnostic and Statistical Manual of Mental Disorders 4th edition (DSM-IV). The diagnosis of MDD was then confirmed by Mini-International Neuropsychiatric Interview Control (M.I.N.I) (Sheehan et al., 1998) . Seventeen control subjects were recruited from the community in Tottori, Japan via an official employment agency. They met neither current nor lifetime axis I disorders of DSM-IV, which was then confirmed by M.I.N.I. Exclusion criteria for all subjects were as follows; (1) somatic disorders such as diabetes, chronic inflammatory disease, autoimmune disease, endocrine disease, and neoplasm, which directly or the treatment of which could influence insulin resistance or plasma cortisol levels; (2) clinical evidence of other central nervous system disorders based on a clinical history and medical examination. Mental ability was examined using the Mini-Mental State Examination (Folstein et al., 1975 ) with a cut-off point of 24; (3) a current or past history of the abuse of illegal drugs or other substances such as benzodiazepines and alcohol; (4) past history of a head injury; and (5) taking any psychotropic drug such as antipsychotics, antidepressants, and mood stabilizers for the preceding two weeks prior to this study because these drugs are known to influence the HPA axis and insulin resistance (Bergman and Ader, 2005; Bschor et al., 2011; Kunzel et al., 2003; Mondelli et al., 2010) .
This study was approved by the Ethics Committee of Tottori University Faculty of Medicine and all subjects gave written informed consent after a full explanation of the study.
Physical measurements and depression scale assessment
The heights (m) and weights (kg) of elderly MDD subjects were measured on admission, and just before this study for the control subjects. The Hamilton depression scale (HAM-D17) (Hamilton, 1960) was assessed in elderly MDD subjects.
Assessment of HPA function
The DEX/CRH test is the most sensitive measurement of HPA axis regulation (Kunugi et al., 2012) , and was, thus, conducted to assess HPA axis regulation in all subjects. The test was performed with a PO pretreatment of 1.5 mg DEX ('decadron' 0.5 mg, Nichiiko Pharmaceutical Corporation, Toyama, Japan) at 23:00 h. An IV catheter with heparinized physiological saline was inserted into a forearm vein at 14:30 h on the following day, and 100 μg human CRH (hCRH 'TANABE', Mitsubishi Tanabe Pharma Corporation, Osaka, Japan) was injected through the catheter at 15:00 h immediately after the first ( ¼ 0 min) blood sampling. Blood samples were taken 30, 60, and 90 min after the injection of CRH in order to measure plasma ACTH and cortisol concentrations. Subjects rested supine in hospital beds throughout the test. Blood samples were cooled in ice water, rapidly centrifuged in a tube for 10 min at 3000 rpm at 4 1C, and then stored at À 20 1C until later analyses. Plasma ACTH and cortisol concentrations were measured using an electrochemiluminescent immunoassay and chemiluminescent enzyme immunoassay, respectively, at SRL Co. (Tokyo, Japan). The limits of detection for ACTH and cortisol were 5.0 pg/ml and 1.0 μg/dl, respectively. ACTH base and Cort base were defined as the plasma concentrations of ACTH and cortisol, respectively, in the blood sample obtained at 15:00 h. ACTH 30 , ACTH 60 , and ACTH 90 were defined as the plasma ACTH concentrations measured 30, 60, and 90 min, respectively, after the IV infusion of CRH. Cort 30, Cort 60, and Cort 90 were similarly designated for plasma cortisol concentrations. The area under the time curve (AUC) was calculated according to the trapezoidal rule (e.g. Cort AUC for the AUC of cortisol). Cort peak was the peak value of the plasma cortisol concentration in response to CRH. ACTH AUC and ACTH peak were defined in a similar manner. Regarding criteria for the suppression of cortisol levels with DEX, we followed those described in a previous study (Kunugi et al., 2012) , in which abnormal "non-suppression" was defined as Cort base of Z5.0 μg/dl irrespective of the size of Cort peak, and "intermediate-suppression" as Cort base of o 5.0 μg/dl and Cort peak of Z 5.0 μg/dl.
Assessment of insulin resistance
In the present study, insulin resistance was assessed with the homeostasis model assessment of insulin resistance (HOMA-R) because it is one of the most extensively used measurements of insulin resistance in clinical settings (Wallace et al., 2004) . Its formula is the basal insulin level multiplied by the basal plasma glucose concentration divided by 22.5. Normal values were previously estimated as 1.62 7 0.96 (Matthews et al., 1985) . After overnight fasting, blood samples were collected to determine plasma glucose and insulin concentrations. Plasma glucose levels were measured using an enzymatic assay and plasma insulin levels were measured using a chemiluminescent immune assay at SRL Co.
Schedule of the hormonal examination
Blood samples were collected on the first day. The PO pretreatment with 1.5 mg DEX was conducted on the second day at 23:00 h, and the DEX/CRH test was conducted on the third day.
Statistical analysis
In order to make comparisons between patient and control groups, an unpaired t-test was used to assess differences in the following items; age, BMI, and fasting blood sugar (FBS). The Mann-Whitney test was used to assess differences in the following items; Cort peak, ACTH peak , Cort AUC, ACTH AUC , and HOMA-R. Fisher's exact test was used to assess differences in the ratio of sex, non-suppression, and intermediate-suppression between the two groups. Spearman rank correlation coefficients were determined to assess the relationships among age, BMI, HAMD, and hormonal parameters, such as ACTH, cortisol, and HOMA-R because of the strongly skewed distribution of these hormonal parameters. A value of p o 0.05 was considered significant. Data analyses were performed using SSPS for Windows 17.0 (SSPA Inc. Chicago).
Results
The demographic and clinical characteristics of the elderly MDD patients and control subjects are shown in Table 1 . No significant differences were observed in these characteristics or FBS, Cort peak , Cort AUC, ACTH peak , ACTH AUC , and HOMA-R between the two groups ( Table 2 ). The ratio of the number of participants assessed as abnormal, non-, and intermediate-suppression in the DEX/CRH test was significantly higher in the patient group than in the control group (Fisher's exact test; po0.05, φ coefficient 0.39) ( Table 3) .
Metabolic characteristics, endocrinal responses, age, and HAMD for the elderly MDD subjects, controls, and all subjects are shown in Table 4 . No correlation was observed between BMI and endocrinal parameters in all subjects, in the control subjects, and in the elderly MDD patients, with the exception of a correlation between BMI and HOMA-R in all subjects (Rho¼ 0.48; po0.05) and in the control subjects (Rho¼0.76; po0.05). However, this correlation was not found in the elderly MDD patients. Regarding the relationship between HPA axis function and insulin resistance, indices of the HPAaxis, Cort peak and Cort AUC did not correlate with HOMA-R in all subjects and in the control subjects. However, Cort AUC and Cort peak both correlated with HOMA-R in the elderly MDD patients (Rho¼ 0.56; po0.05, Rho¼ 0.54; po0.05, respectively). The relationships between Cort AUC , Cort peak, and HOMA-R in all subjects, the control subjects, and the elderly MDD patients are shown in Fig. 1 . In the elderly MDD patients, the total HAMD score correlated with Cort peak (Rho¼0.80; po0.05) and Cort AUC (Rho¼0.83; po0.05), as shown in Fig. 2 . The total HAM-D score did not correlate with HOMA-R. Furthermore, no correlation was observed between age and either BMI or endocrinal parameters.
Discussion
In the present study, correlations were observed between Cort AUC or Cort peak obtained from the DEX/CRH test and HOMA-R, an index of insulin resistance, in the elderly MDD patients. This is the first study to directly demonstrate the relationship between HPA axis dysregulation, as revealed by the DEX/CRH test, and insulin resistance in elderly MDD patients.
The correlation between cortisol dysregulation and insulin resistance was only observed in the elderly MDD patients. Additionally, the ratio of participants showing abnormal, non-, or intermediatesuppression of the DEX/CRH test was higher in the elderly MDD patients. Thus, although this study had a cross-sectional design in nature and, thus, cannot concretely conclude any relationship between elevated cortisol levels and insulin resistance, our results are consistent with the hypothesis that depressive states affect cortisol dysregulation, and also that hypercortisolemia leads to the development of insulin resistance in elderly patients with depression.
A correlation was observed between BMI and HOMA-R in the control subjects, but not in the MDD patients. A previous study reported that obesity was associated with an increased risk of developing insulin resistance. In obese individuals, adipose tissue releases increased amounts of non-esterified fatty acids, glycerol, hormones, pro-inflammatory cytokines, and other factors that are involved in the development of insulin resistance. The lack of a significant relationship between obesity and insulin resistance in elderly MDD patients may be explained by the relatively larger effect of elevated cortisol levels on insulin resistance in this population.
To examine the relationship between cortisol and HOMA-R, a multivariate analysis was considered to be appropriate in order to assess the contribution of BMI and age; previous studies demonstrated that BMI was positively associated with insulin resistance (Mihic and Modi, 2008; Tjokroprawiro, 2006) , and a weak negative association has also been reported between BMI and plasma cortisol levels (Travison et al., 2007) . On the other hand, the HPA axis associated with MDD was reported to be more prevalent in the elderly (Hatzinger et al., 2011) , and insulin resistance and the prevalence of type 2 diabetes have both been shown to increase with aging (Rowe et al., 1983) , as discussed above. However, no correlation was observed between BMI and plasma cortisol levels or HOMA-R nor between age and plasma cortisol levels or HOMA-R, in the elderly MDD patients in the present study; therefore, we adopted a univariate analysis. Our results also indicated that the severity of the psychiatric condition positively correlated with plasma cortisol levels. Recent studies demonstrated that patients with more severe depression had higher cortisol levels (Kunugi et al., 2006; Owashi et al., 2008) , and our results were consistent with these findings. On the other hand, we did not find any correlation between the severity of the psychiatric condition and the index of insulin resistance assessed with HOMA-R. Therefore, we hypothesized that a depressive state may affect cortisol dysregulation, and that hypercortisolemia may then worsen insulin resistance in elderly patients with depression.
In the present study, no significant differences were observed in any hormonal parameter such as Cort peak and Cort AUC between control subjects and the elderly MDD patients (Table 2) . Although previous studies reported significant differences in these parameters between these groups (Kunugi et al., 2004) , others disproved such differences in HPA regulation between healthy controls and depressed subjects (Carpenter et al., 2009; Gervasoni et al., 2004) . HPA axis dysregulation was not detected in patients with the following attributes: being outpatients, chronic patients, long-term sick leave patients, and atypical depression patients (Kunugi et al., 2012 ), who were not investigated in our study. Since the ratio of abnormal, non-, and intermediate-suppression was significantly higher in the patient group, the weak statistical power due to the small number of subjects may be the reason for the apparent lack of significant differences in hormonal parameters between the two groups.
The number of adults over 60 years old is increasing in many developed countries (Christensen et al., 2009) . Although previous studies demonstrated that depression indirectly influenced the physical health of the elderly through cognitive impairments and social factors such as a lower income and poor social support (Mezuk et al., 2012; Takeshita et al., 2002) , depression, per se, may directly affect the physical health of the elderly through insulin resistance and type 2 diabetes. From a clinical perspective, clinicians should consider the risk of type 2 diabetes when they treat elderly MDD patients.
The limitations of the present study are as follows: (1) the small sample size; the number of participants in this study was relatively small. The responses of the HPA axis, such as cortisol responses, were highly variable (Cort peak ; mean 5.8, S.D. 7.6, Cort AUC ; mean 407.5, S.D. 542, for all subjects); thus, a large sample size is more desirable. (2) The cross-sectional design; a longitudinal study is required to establish a relationship between depression, HPA dysregulation, and insulin resistance. (3) The limited characteristics of the subjects; only inpatients and the Fig. 1 . Shows the correlation between Cort peak and Cort AUC and the DEX/CRH and HOMA-R of all the subjects, the control subjects, and the elderly MDD subjects. Cort AUC and Cort peak both correlated with HOMA-R only in the elderly MDD subjects (Rho ¼ 0.56; p o 0.05, Rho ¼0.54; po 0.05, respectively). elderly were included in this study. Outpatients, remitted patients, and other generations of subjects are needed to more accurately examine the relationship between HPA dysregulation, insulin resistance, and age; however, it is possible that the correlation observed between cortisol levels and insulin resistance may be specific to elderly patients. (4) Other limitations include the lack of consideration of the duration of the current depressive episode, frequency of depressive episodes in the life of the patient, the nature of the depressive state, such as psychotic or non-psychotic, typical or atypical, and a family history of diabetes. (5) The multiplicity of the statistical tests was not considered, and, thus, in combination with the small sample size, the results of the present study should be taken as exploratory at best.
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